4.5 Article

Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK

Journal

JOURNAL OF MEDICAL GENETICS
Volume 48, Issue 4, Pages 266-272

Publisher

B M J PUBLISHING GROUP
DOI: 10.1136/jmg.2010.086538

Keywords

-

Funding

  1. National Health and Medical Research Council of Australia (NHMRC) [107359, 211172, 566946, 402761, 520018]
  2. Cancer Councils New South Wales [77/00, 06/10]
  3. Victoria and Queensland [371]
  4. US National Institutes of Health [CA-83115-01A2]
  5. Victorian Cancer Agency [ECSG07_010]
  6. University of Sydney Medical Foundation
  7. Cancer Research UK [C588/A4994, C588/A10589, C8216/A6129]
  8. National Institute of Health [CA83115]
  9. Cancer Research UK [10589] Funding Source: researchfish

Ask authors/readers for more resources

Background CDKN2A mutations confer a substantial risk of cutaneous melanoma; however, the magnitude of risk is uncertain. Methods The study estimated the hazard ratio (HR) and the average age specific cumulative risk (ie, penetrance) of reported melanoma for CDKN2A mutation carriers in case families using a modified segregation analysis of the first and higher degree relatives of 35 population-based cases. The study sample included 223 relatives of 13 melanoma cases diagnosed when aged 18-39 years from Melbourne, Sydney and Brisbane, Australia, and 322 relatives of 22 melanoma cases diagnosed at any age from Yorkshire, UK. Results The estimated HR for melanoma for mutation carriers relative to the general population decreased with regions of increasing ambient ultraviolet (UV) irradiance, being higher for the UK than Australia (87, 95% CI 50 to 153 vs 31, 95% CI 20 to 50, p=0.008), and across Australia, 49 (95% CI 24 to 98) for Melbourne, 44 (95% CI 22 to 88) for Sydney, and 9 (95% CI 2 to 33) for Brisbane (p=0.02). Penetrance did not differ by geographic region. It is estimated that 16% (95% CI 10% to 27%) of UK and 20% (95% CI 13% to 30%) of Australian CDKN2A mutation carriers would be diagnosed with melanoma by age 50 years, and 45% (95% CI 29% to 65%) and 52% (95% CI 37% to 69%), respectively, by age 80 years. Conclusions Contrary to the strong association between UV radiation exposure and melanoma risk for the general population, CDKN2A mutation carriers appear to have the same cumulative risk of melanoma irrespective of the ambient UV irradiance of the region in which they live.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available